Subscribe to Newsletter
Subspecialties Business and Innovation, Comprehensive

Espansione Group: Pioneering Light-Based Solutions in Ophthalmology

sponsored by Espansione Group

Credit: Images supplied by the Espansione Group

Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, strives to deliver the highest standards in the ophthalmic industry. With a strong commitment to improving patient care, the company has developed and introduced cutting-edge solutions for a wide range of ocular conditions, from the ocular surface to the posterior segment and beyond, with new applications being continuously researched in fields from dermatology to neurology.

About LM® LLLT and eye-light®

At the heart of the company’s innovation pipeline is Light Modulation® Low-level Light Therapy (LM® LLLT), its patented photobiomodulation (PBM) technology available on the eye-light® solution. LM® LLLT is a groundbreaking approach that harnesses monochromatic light waves to stimulate cellular activity through a number of mechanisms of action (e.g., ATP production stimulus, reduction of the oxidative stress).

Our flagship solution, eye-light®, combines the efficacy of LM® LLLT with the versatility of OPE® IPL (Optimal Power Energy® Intense Pulsed Light). OPE® IPL is well-known to be effective in addressing inflammatory conditions – a common contributor to a number of conditions – by thermally regulating the treatment area, reducing bacterial load in the process​​.

Revolutionizing patient care

Espansione’s technologies have shown remarkable results in managing a variety of anterior segment conditions. From treating chalazia to managing complex autoimmune conditions such as Sjögren’s Syndrome, from providing a non-invasive, painless solution for dry eye disease all the way to dAMD via the LightWave I study, these technologies have reshaped patient care. They offer effective, safe, and painless treatment options to a number of conditions – with over 50 papers and counting published worldwide on eye-light® alone​​.

Preventing iatrogenic dry eye in cataract surgery: A breakthrough study

One of the latest pieces of research focusing on LM® LLLT’s ability to elevate patient care is a recent study published in the British Journal of Ophthalmology. The research focused on preventing iatrogenic dry eye disease (DED) in healthy patients undergoing senile cataract surgery – a procedure aimed at improving patients’ quality of life, which can, however, (i.e., in ~30% of instances) result in the development of major ocular surface discomfort.

This prospective, interventional, randomized, controlled, double-masked clinical trial involved 153 healthy patients, who underwent two sessions of LM® LLLT (or sham treatment). The protocol saw one session of Red LM® LLLT being administered one week before and one week after the cataract surgery.

The results were groundbreaking: patients treated with LM® LLLT showed significantly lower Ocular Surface Disease Index (OSDI) scores (9.0±9.0 vs 18.2±17.9) and higher Non-Invasive Break-up Time (NIBUT) values (12.5±6.6 seconds vs 9.0±7.8 seconds) compared to the control group at 30 days post-surgery. Moreover, the Meiboscore values for Meibomian Gland Loss (MGL) were significantly lower in the LM® LLLT group compared to the control group, highlighting the therapy's efficacy in maintaining ocular surface integrity​​.

The study emphasized the seamless integration of the LM® LLLT treatment into the routine workflow of cataract surgery, making it a convenient, non-invasive, and highly effective prophylactic intervention against postoperative DED​​.

In conclusion, Espansione Group continues to lead the way in innovative patient care, with LM® LLLT and eye-light® at the forefront of this revolution. As evidenced by rigorous clinical research, these technologies not only promise but deliver substantial improvements in patient outcomes, particularly in the challenging arena of cataract surgery and dry eye disease prevention.

Discover the revolutionary Light Modulation® LLLT!

Click here to view the video: A New Paradigm in Ophthalmology and Beyond

Disclaimer: Not all solutions and use cases available in all countries. Every piece of information shown ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Related Product Profile
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: